FDA Approves Simponi For Ulcerative Colitis
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.